| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/15/2004 | DE10227938A1 Pharmazeutische Zubereitung, Verfahren zu ihrer Herstellung sowie deren Verwendung A pharmaceutical preparation, processes for their preparation and their use |
| 01/15/2004 | DE10227914A1 Pharmazeutische Zubereitung mit retardierender Wirkstofffreisetzung, Verfahren zu ihrer Herstellung und Verwendung Pharmaceutical formulation having retarded active substance release, methods for their preparation and use |
| 01/15/2004 | DE10227232A1 Saure Insulinzubereitungen mit verbesserter Stabilität Acidic insulin preparations with improved stability |
| 01/15/2004 | CA2494508A1 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | CA2493906A1 Therapeutics for diabetes mellitus |
| 01/15/2004 | CA2493860A1 Marker genes for determining renal toxicity |
| 01/15/2004 | CA2492535A1 New quinuclidine amide derivatives |
| 01/15/2004 | CA2492037A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 01/15/2004 | CA2492033A1 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| 01/15/2004 | CA2492026A1 New pharmaceutical compositions based on new anticholinergics and pde-iv inhibitors |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | CA2491712A1 New drug combinations based on magnesium salts and fibrinolytics |
| 01/15/2004 | CA2491687A1 A robust, inducible cardiac preferred expression system for transgenesis |
| 01/15/2004 | CA2491573A1 Methods of treating microbial infections in humans and animals |
| 01/15/2004 | CA2491479A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | CA2491474A1 Boroproline compound combination therapy |
| 01/15/2004 | CA2491466A1 Methods and compositions relating to isoleucine boroproline compounds |
| 01/15/2004 | CA2491451A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | CA2491406A1 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | CA2491382A1 Compositions comprising panthetine for the treatment of dyslipidemia |
| 01/15/2004 | CA2491321A1 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | CA2491286A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | CA2491217A1 New drug combinations based on sodium channel blockers and magnesium salts |
| 01/15/2004 | CA2491128A1 Treatment for eye disorder |
| 01/15/2004 | CA2491127A1 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | CA2490988A1 Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors |
| 01/15/2004 | CA2490952A1 Vitamin-containing system for stabilising the immune response of animals |
| 01/15/2004 | CA2490714A1 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | CA2490707A1 Method of using ryanodine antagonists in treating neural injury |
| 01/15/2004 | CA2490494A1 Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds |
| 01/15/2004 | CA2490470A1 Pyrazole urea neuropeptide y y5 receptor antagonists |
| 01/15/2004 | CA2490463A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | CA2490142A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | CA2490097A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | CA2489563A1 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/15/2004 | CA2489562A1 Mitotic kinesin binding site |
| 01/15/2004 | CA2488736A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 01/15/2004 | CA2487856A1 Methods for identification of compounds modulating insulin resistance |
| 01/15/2004 | CA2460051A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/14/2004 | EP1380594A1 Fibroblast growth factor-10 |
| 01/14/2004 | EP1380593A1 Soluble rage protein |
| 01/14/2004 | EP1380305A1 Photodynamic therapy for the enhancement of vascular permeability |
| 01/14/2004 | EP1380304A2 Process for the improvement of spermatozoa fertilization activity |
| 01/14/2004 | EP1380303A1 Combination therapy to treat hepatitis B virus |
| 01/14/2004 | EP1380291A1 PDE IV inhibitors for treating multiple sclerosis |
| 01/14/2004 | EP1380290A1 Cross-beta structure pathway and its therapeutic relevance |
| 01/14/2004 | EP1380205A1 Experimental animals for evaluation of therapeutic effects on corneal epithelial damages |
| 01/14/2004 | EP1379873A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 01/14/2004 | EP1379694A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna |
| 01/14/2004 | EP1379688A2 Polymorphisms in the human cmoat gene and uses thereof |
| 01/14/2004 | EP1379679A2 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 01/14/2004 | EP1379662A2 Sulfatases and methods of use thereof |
| 01/14/2004 | EP1379654A2 Intracellular signaling molecules |
| 01/14/2004 | EP1379652A2 Human nucleic acid molecules and polypeptides encoding a human ion channel expressed in spinal cord and brain |
| 01/14/2004 | EP1379648A1 Full-length human cdnas encoding potentially secreted proteins |
| 01/14/2004 | EP1379638A2 Implantation serine proteinases |
| 01/14/2004 | EP1379637A2 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| 01/14/2004 | EP1379630A2 Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| 01/14/2004 | EP1379628A2 Kinases and phosphatases sequences, and use thereof |
| 01/14/2004 | EP1379542A2 Treatment of tumours |
| 01/14/2004 | EP1379524A2 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 01/14/2004 | EP1379523A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 01/14/2004 | EP1379517A2 Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 01/14/2004 | EP1379513A1 Prodrugs of cox-2 inhibitors |
| 01/14/2004 | EP1379510A1 Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers |
| 01/14/2004 | EP1379337A1 Generation of pharmaceutical agent particles using focused acoustic energy |
| 01/14/2004 | EP1379279A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine |
| 01/14/2004 | EP1379276A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 01/14/2004 | EP1379275A2 Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses |
| 01/14/2004 | EP1379271A1 Method for treating von willebrand's disease |
| 01/14/2004 | EP1379269A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease |
| 01/14/2004 | EP1379265A2 Short bioactive peptides and methods for their use |
| 01/14/2004 | EP1379259A1 Methods of treating syndrome x with aliphatic polyamines |
| 01/14/2004 | EP1379250A2 A method of treating cancer |
| 01/14/2004 | EP1379248A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors |
| 01/14/2004 | EP1379247A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases |
| 01/14/2004 | EP1379238A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| 01/14/2004 | EP1379235A2 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 01/14/2004 | EP1379231A2 Pharmacologically active strong acid solutions |
| 01/14/2004 | EP1379229A2 A jasmonate pharmaceutical composition for treatment of cancer |
| 01/14/2004 | EP1379225A2 Novel medicament compositions based on anticholinergic agents and endothelin antagonists |
| 01/14/2004 | EP1379224A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 01/14/2004 | EP1379207A1 Composition for freshening nostrils and sinus cavities |
| 01/14/2004 | EP1379203A1 Condom with an erectogenic composition |
| 01/14/2004 | EP1379133A2 Two-phase processing of thermosensitive polymers for use as biomaterials |
| 01/14/2004 | EP1379130A2 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 01/14/2004 | EP1115404B1 Use of prostanoid antagonists for the treatment of primary headache disorders |
| 01/14/2004 | EP1056448B1 Pharmaceutical combinations containing tramadol |
| 01/14/2004 | EP1019059A4 USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION |
| 01/14/2004 | EP1014989B1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 01/14/2004 | EP1014965B1 Dietary compositions for enhancing metabolism and alleviating oxidative stress |
| 01/14/2004 | EP1011678A4 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| 01/14/2004 | EP0938321B1 Combinations comprising vx478, zidovudine and 3tc for use in the treatment of hiv |
| 01/14/2004 | CN1468309A Anti-il-12 antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468308A Anti-tnf antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468307A Anti-dual integrin antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468305A Modulation of the transcription of pro-inflammatory gene products |
| 01/14/2004 | CN1468296A Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 01/14/2004 | CN1468259A Immunotherapy for chronic myelocytic leukemia |